门静脉灌注治疗肝癌瘤栓性腹水

Intraportal Vein Infusion of Urokinase and Anticarciogen in Treatment of Hepatocellular Carcinoma with Tumor Thrombus in Main Portal Vein and Intractable ascites

本文报告了6例肝癌并门静脉主干瘤栓顽固性腹水症患者经门静脉腔内灌注溶栓化疗药物治疗的临床结果。本组病例年龄在38～52岁之间,平均年龄43岁。临床特点为进行性顽固性腹水,门静脉造影显示门脉主干瘤栓。选择尿激酶、丝裂霉素和表阿霉素作为溶栓化疗药物。治疗后,门静脉主干压由治疗前平均31.50CmH_2O下降至27.16CmH_2O,门静脉血运通畅性增加,侧枝循环减少,短期内5例腹水明显消退。术后1～15个月随访结果表明,该疗法可显著改善病人的生活质量,协同提高LP-TAE的治疗效果,对延长患者生存期具有积极意义。

This paper reported thd clinic trial of 6 patients with hepatocellular carcinoma associated with tumor thrombus in main portal vein and intractable ascites, administered by intraportal vein infusion of urokinase and chemotherapeutic agents. Of the group, aged 3.8-52 years, mean 43, With the clinical characteristic of progressive intractable ascites and tumor cell thrombus in portal venography. Urokinase, MMC, and 4ep'ADE were selected for the procedure. After the therapy, main portal vein pressure was reduced from 31. 50CmH2O (mean) to 27.16CmH2O, blood patency of portal vein was increaced, collateral circulation was decreased, and ascites in 5 cases disappeared obviously during short term. The results of 1-15 months follow-up show that this therapy can evidently improve the pateint's life quality, raised the effect of LP-TAE, and prolong the paleint's survival time.